Searching across hundreds of databases
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Integrated Clinical Trials is a virtual database currently indexing clinical trials from: EU Clinical Trials Register and ClinicalTrials.gov.
(last updated: Nov 28, 2022)
Clinical Trials Information| Database | Title | Recruitment | Conditions | Intervention | Sponsored By | Gender | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Clinicaltrials.gov | Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma | Unknown status | Lymphoma, Small Intestine Cancer | Biological, Drug, Drug, Drug, Drug, Genetic, Other, Other, Other - alemtuzumab, cyclophosphamide, doxorubicin hydrochloride, prednisolone, vincristine sulfate, polymerase chain reaction, flow cytometry, laboratory biomarker analysis, pharmacological study | Cancer Research UK, Other | 18 Years - N/A | Phase 1 | Interventional | RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from growing. Giving alemtuzumab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of alemtuzumab when given together with combination chemotherapy and to see how well it works in treating patients with stage I , stage II , stage III, or stage IV peripheral T-cell lymphoma. | ||
|
Clinicaltrials.gov | NG-Nitro-L-Arginine in Treating Patients With Advanced Solid Tumors | Terminated | Unspecified Adult Solid Tumor, Protocol Specific | Drug, Other, Other, Procedure, Procedure - NG-nitro-L-arginine, laboratory biomarker analysis, pharmacological study, computed tomography, dynamic contrast-enhanced magnetic resonance imaging | Cancer Research UK, Other | 18 Years - N/A | Phase 1 | Interventional | RATIONALE: NG-nitro-L-arginine may stop the growth of tumor cells by disrupting blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of NG-nitro-L-arginine in treating patients with advanced solid tumors. | ||
|
Clinicaltrials.gov | Study of Genes and the Environment in Patients With Endometrial Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom | Unknown status | Endometrial Cancer | Genetic, Other, Other - polymorphism analysis, laboratory biomarker analysis, questionnaire administration | Cancer Research UK, Other | Female | 18 Years - 74 Years | Observational | RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This study is looking at genetic susceptibility to cancer and interactions between genes and the environment in patients with endometrial cancer. | ||
|
Clinicaltrials.gov | Study of Genes and Environment in Patients With Breast Cancer in the East Anglia Region of the United Kingdom | Unknown status | Breast Cancer | Genetic, Other, Other - polymorphism analysis, laboratory biomarker analysis, questionnaire administration | Cancer Research UK, Other | 18 Years - 70 Years | Observational | RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This study is looking at genetic susceptibility to cancer and interactions between genes and the environment in patients with breast cancer. | |||
|
Clinicaltrials.gov | Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Completed | Brain and Central Nervous System Tumors | Biological, Biological, Drug, Other, Other, Procedure, Radiation - glioblastoma multiforme multipeptide vaccine IMA950, sargramostim, temozolomide, laboratory biomarker analysis, pharmacological study, adjuvant therapy, radiation therapy | Cancer Research UK, Immatics Biotechnologies GmbH, Other, Industry | 18 Years - N/A | Phase 1 | Interventional | RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving vaccine therapy together with temozolomide and radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy when given together with temozolomide and radiation therapy in treating patients with newly diagnosed glioblastoma multiforme. | ||
|
Clinicaltrials.gov | Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer | Terminated | Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Biological, Biological, Drug, Drug, Other, Other - MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes, aldesleukin, cyclophosphamide, fludarabine phosphate, laboratory biomarker analysis, pharmacological study | Cancer Research UK, Other | 18 Years - N/A | Phase 1 | Interventional | RATIONALE: Placing a gene into T cells may improve the body's ability to recognize cancer cells and build an immune response to fight cancer. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Biological therapies, such as aldesleukin, may stimulate the immune system in different ways and stop cancer cells from growing. Giving specially treated T cells together with cyclophosphamide, fludarabine phosphate, and aldesleukin may kill more tumor cells. PURPOSE: This phase I clinical trial is studying the side effects and best dose of treated T cells when given together with cyclophosphamide, fludarabine phosphate, and aldesleukin in treating patients with cancer. | ||
|
Clinicaltrials.gov | MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery | Completed | Pancreatic Cancer | Drug, Drug, Other, Other, Other - Notch signaling pathway inhibitor MK0752, gemcitabine hydrochloride, imaging biomarker analysis, laboratory biomarker analysis, pharmacological study | Cancer Research UK, Other | 18 Years - N/A | Phase 1 | Interventional | RATIONALE: MK0752 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving MK0752 together with gemcitabine hydrochloride may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving MK0752 together with gemcitabine hydrochloride and to see how well it works in treating patients with stage III or IV pancreatic cancer that cannot be removed by surgery. | ||
|
Clinicaltrials.gov | Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer | Unknown status | Prostate Cancer | Drug, Drug, Genetic, Genetic, Genetic, Genetic, Other, Procedure, Procedure - antiandrogen therapy, releasing hormone agonist therapy, DNA analysis, RNA analysis, comparative genomic hybridization, gene expression analysis, laboratory biomarker analysis, diffusion-weighted magnetic resonance imaging, magnetic resonance spectroscopic imaging | Cancer Research UK, Other | Male | N/A - N/A | N/A | Interventional | RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at blood and tissue samples from patients with prostate cancer receiving androgen deprivation therapy. | |
|
Clinicaltrials.gov | Donor Umbilical Cord Blood Transplant After Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease | Unknown status | Hematopoietic/Lymphoid Cancer | Drug, Drug, Drug, Drug, Other, Procedure, Procedure, Radiation - cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, laboratory biomarker analysis, nonmyeloablative allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation | Cancer Research UK, Other | 2 Years - 60 Years | Phase 2 | Interventional | RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of abnormal cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining abnormal cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying the side effects of donor umbilical cord blood transplant after cyclophosphamide, fludarabine phosphate, and total-body irradiation in treating patients with hematologic disease. | ||
|
Clinicaltrials.gov | Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer | Completed | Gastric Cancer, Head and Neck Cancer, Lymphoma, Lymphoproliferative Disorder, Nonneoplastic Condition | Biological, Other, Other - EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine, laboratory biomarker analysis, pharmacological study | Cancer Research UK, Other | 18 Years - N/A | Phase 1 | Interventional | RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with Epstein-Barr virus and cancer. | ||
|
Clinicaltrials.gov | Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer | Active, not recruiting | Breast Cancer | Biological, Drug, Other, Procedure, Procedure, Procedure - trastuzumab, lapatinib ditosylate, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery | Institute of Cancer Research, United Kingdom, University of Manchester, Manchester University NHS Foundation Trust, Cancer Research UK, Novartis, Other, Other, Other, Other, Industry | Female | 18 Years - N/A | Phase 3 | Interventional | RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trastuzumab or lapatinib ditosylate is more effective in treating women with early breast cancer. Update June 2013: Since the initial development of EPHOS-B in 2007 more evidence in relation to safety and efficacy of anti-HER2 therapies are now available, and in particular, a growing body of evidence that combinations of two anti-HER2 therapies are more effective than monotherapies. Therefore this study has been amended (PART 2) to a 1:1:2 ratio to control, perioperative trastuzumab or the combination of lapatinib and trastuzumab. PURPOSE: This randomized phase III trial is studying trastuzumab to see how well it works compared with lapatinib ditosylate (and in since June 2013 - compared with a combination of lapatinib and trastuzumab) in treating women with early breast cancer. | |
|
Clinicaltrials.gov | Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer | Unknown status | Prostate Cancer | Genetic, Genetic, Other, Other - gene expression analysis, protein analysis, biologic sample preservation procedure, laboratory biomarker analysis | Cancer Research UK, Other | Male | N/A - N/A | Observational | RATIONALE: Studying samples of tissue, blood, and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat the cancer. PURPOSE: This research study is looking at tissue, blood, and urine samples from patients with advanced prostate cancer. | ||
|
Clinicaltrials.gov | Genes and Other Risk Factors for Second Primary Breast Cancer in Women With Breast Cancer and Their Female Family Members and Friends | Unknown status | Breast Cancer | Genetic, Genetic, Genetic, Genetic, Other, Other, Other - DNA analysis, genetic linkage analysis, loss of heterozygosity analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review, questionnaire administration | Cancer Research UK, Other | Female | N/A - 70 Years | Observational | RATIONALE: Studying samples of blood, urine, and tumor tissue in the laboratory from patients with cancer and their female relatives and friends may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at genes and other risk factors for second primary breast cancer in women with breast cancer and in their female family members and friends. | ||
|
Clinicaltrials.gov | Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment | Withdrawn | Lymphoma | Biological, Biological, Dietary Supplement, Drug, Drug, Drug, Other, Other - filgrastim, rituximab, Se-methyl-seleno-L-cysteine, carboplatin, etoposide, ifosfamide, laboratory biomarker analysis, pharmacological study | Cancer Research UK, Other | 18 Years - N/A | Phase 1/Phase 2 | Interventional | RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer cell-killing substances to them. Drugs used in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Se-methyl-seleno-l-cysteine may help reduce the side effects of chemotherapy. PURPOSE: This phase I/II trial is studying the side effects and best dose of Se-methyl-seleno-l-cysteine when given together with rituximab, ifosfamide, carboplatin, and etoposide and to see how well it works in treating patients with diffuse large B-cell lymphoma that has relapsed or not responded to treatment. | ||
|
Clinicaltrials.gov | Study of Genes and the Environment in Patients With Colorectal Cancer in the East Anglia Region of the United Kingdom | Unknown status | Colorectal Cancer | Genetic, Other, Other - polymorphism analysis, laboratory biomarker analysis, questionnaire administration | Cancer Research UK, Other | 18 Years - 69 Years | Observational | RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This study is looking at genetic susceptibility for cancer and interactions between genes and the environment in patients with colorectal cancer. | |||
|
Clinicaltrials.gov | Blood Samples From Healthy Volunteers for Genetic Studies in the East Anglia Region of the United Kingdom | Unknown status | Healthy, no Evidence of Disease | Genetic, Other, Other - polymorphism analysis, laboratory biomarker analysis, questionnaire administration | Cancer Research UK, Other | 35 Years - 69 Years | Observational | RATIONALE: Studying samples of blood from healthy volunteers in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This study is looking at genetic susceptibility to cancer and interactions between genes and the environment in healthy volunteers. | |||
|
Clinicaltrials.gov | Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer | Completed | Breast Cancer | Drug, Other, Other - abiraterone acetate, laboratory biomarker analysis, pharmacogenomic studies | Cancer Research UK, Other | Female | 18 Years - N/A | Phase 1/Phase 2 | Interventional | RATIONALE: Abiraterone acetate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of abiraterone acetate and to see how well it works in treating postmenopausal women with advanced or metastatic breast cancer. | |
|
Clinicaltrials.gov | Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer | Terminated | Breast Cancer | Drug, Drug, Genetic, Genetic, Other, Other - SOD1 inhibitor ATN-224, exemestane, protein expression analysis, proteomic profiling, laboratory biomarker analysis, pharmacological study | Cancer Research UK, Other | Female | 18 Years - N/A | Phase 2 | Interventional | RATIONALE: Exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ATN-224 may stop the growth of breast cancer by blocking blood flow to the tumor. It is not yet known whether giving exemestane together with ATN-224 is more effective than giving exemestane alone in treating patients with recurrent or advanced breast cancer. PURPOSE: This randomized phase II trial is studying the side effects of exemestane given together with or without ATN-224 and to see how well it works in treating postmenopausal women with recurrent or advanced breast cancer. | |
|
Clinicaltrials.gov | AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia | Completed | Leukemia | Drug, Other, Other - multikinase inhibitor AT9283, laboratory biomarker analysis, pharmacological study | Cancer Research UK, Other | N/A - 18 Years | Phase 1 | Interventional | RATIONALE: AT9283 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/IIa clinical trial is studying the side effects and best dose of AT9283 in treating young patients with relapsed or refractory acute leukemia. | ||
|
Clinicaltrials.gov | Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom | Unknown status | Bladder Cancer, Brain and Central Nervous System Tumors, Esophageal Cancer, Intraocular Melanoma, Kidney Cancer, Lymphoma, Melanoma (Skin), Pancreatic Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Genetic, Genetic, Other, Other - DNA analysis, polymorphism analysis, laboratory biomarker analysis, questionnaire administration | Cancer Research UK, Other | 18 Years - 69 Years | Observational | RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This study is looking at genetic susceptibility to cancer and interactions between genes and the environment in patients with cancer in East Anglia, Trent, or West Midlands of the United Kingdom. |
Welcome to the RRID Resources search. From here you can search through a compilation of resources used by RRID and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that RRID has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on RRID then you can log in from here to get additional features in RRID such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into RRID you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
